Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 11/20 | 0.48 |
| ▸ | STK17B | O94768 | 8/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14941832 | 0.84 | CYP1A2 (0.44) | STK17ASTK17BCYP1A2LMNATP53 | |
| SCHEMBL1937307 | 0.83 | ESR1 (0.49) | STK17ASTK17BTP53MAPTSLC29A1 | |
| SCHEMBL1934538 | 0.81 | STK17A (0.51) | STK17ASTK17BALDH1A1L3MBTL1 | |
| SCHEMBL28675876 | 0.79 | STK17B (0.40) | STK17ASTK17BCYP1A2LMNATP53 | |
| SCHEMBL22261163 | 0.78 | JAK3 (0.55) | STK17ASTK17BCYP1A2 | |
| SCHEMBL14941801 | 0.78 | PIN1 (0.51) | STK17ACYP1A2LMNATP53MAPT | |
| SCHEMBL1937398 | 0.78 | STK17A (0.56) | STK17ASTK17BALDH1A1L3MBTL1KDM4E | |
| SCHEMBL1938460 | 0.77 | STK17A (0.51) | STK17ASTK17BTP53ALDH1A1L3MBTL1 | |
| SCHEMBL1935303 | 0.77 | STK17B (0.47) | STK17ASTK17BLMNAALDH1A1L3MBTL1 | |
| SCHEMBL1938676 | 0.77 | STK17A (0.51) | STK17ASTK17BCYP1A2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230478-A1 | 4-Alkyl-substituted diaminopyrimidines | Bayer ScienceCrop AG (DE) | 2011-09-22 | — | — | US | disclosed |
| EP-2330904-A2 | 4-ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES | Bayer CropScience AG (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010025863-A2 | 4-ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES | BAYER CROPSCIENCE AG (DE) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230478-A1 | 4-Alkyl-substituted diaminopyrimidines | DPM1, DPYD, POLR1C | STK17A 2888/4885STK17B 3187/4885CYP1A2 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.